The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019

Dong, Wenlan; An, Jing; Ming, Yu; Yin, Peng; Xu, Tingling; Бо, Лю; Zuberbier, Torsten; Zhao, Zuotao; Zhou, Maigeng

doi:10.1016/j.waojou.2021.100604

Cited by 13 publications

(13 citation statements)

References 30 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 80% of AD patients, the condition is exogenous and is caused by sensitization to different air and food allergens, manifested as elevated levels of total IgE and allergen-specific IgE, and positive skin prick and specific patch tests. 14 In exogenous AD, mites play an important role in inducing or aggravating allergic skin lesions and have become the most prevalent allergen (63.3%) in AD children in China. 12,14 While mite allergen-specific immunotherapy was initially used to treat allergic rhinitis or asthma, recent studies Both children were given a combined dupilumab and subcutaneous immunotherapy (SCIT) treatment.…”

Section: Introductionmentioning

confidence: 99%

“…14 In exogenous AD, mites play an important role in inducing or aggravating allergic skin lesions and have become the most prevalent allergen (63.3%) in AD children in China. 12,14 While mite allergen-specific immunotherapy was initially used to treat allergic rhinitis or asthma, recent studies Both children were given a combined dupilumab and subcutaneous immunotherapy (SCIT) treatment. The rationale behind adding dupilumab was to control acute skin inflammation before introducing desensitization therapy, because both children had moderate-to-severe AD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis

Ding

Lai²,

Lu³

2023

Allergol Immunopathol

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that manifests in skin dryness, severe itching, and eczema, and can significantly impact a patient’s quality of life. Current treatment regimens do not prevent the recurrence of the disease and are associated with adverse effects. Here, we report two cases of moderate-to-severe AD in children that were treated with dupilumab, a dual inhibitor of IL-4 and IL-13 signaling, in combination with mite allergen-specific immunotherapy.Case summary: Both patients presented with the diagnosis of AD that was not adequately controlled by the conventional treatment regimen, including topical corticosteroids (TCS), topical calcineurin inhibitors, emollients, and the traditional Chinese medicine treatments. In both patients, AD-associated skin irritation impacted the quality of life, disturbed sleep patterns, and caused stress and anxiety. Patients received treatment with dupilumab and mite allergen-specific immunotherapy in addition to the baseline treatment regimen of external glucocorticoids (TCS) and oral antihistamines. Nine months after beginning of treatment, clinical symptoms, signs, medication scores, and evaluation scale scores of both children significantly improved, and the treatment was associated with an overall good tolerance.Conclusion: A combination of dupilumab and mite allergen-specific immunotherapy in addition to the standard anti-AD treatment improves clinical symptoms and is not associated with increased incidence of adverse effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis

Ding

Lai²,

Lu³

2023

Allergol Immunopathol

View full text Add to dashboard Cite

show abstract

“…During the study period, more than 1 in 6 children younger than 6 years had, at some point, been affected by AD 4 . This represents a significant burden of the disease, warranting effective, efficient, and broadly applicable management strategies that appreciate the complex and variable nature of AD 5 …”

Section: Introductionmentioning

confidence: 99%

“…4 This represents a significant burden of the disease, warranting effective, efficient, and broadly applicable management strategies that appreciate the complex and variable nature of AD. 5 AD is a systemic inflammatory condition, including filaggrin deficiency-induced skin-barrier disruption and microbiome alteration. Targeting the pathogenesis of AD, a multifaceted approach, including skin hydration, measures to strengthen skin barrier integrity, topical anti-inflammatory and antipruritic therapy, antibacterial measures, and the elimination of exacerbating factors, can help achieve disease control and prevention of comorbidities.…”

Section: Introductionmentioning

confidence: 99%

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

Zuberbier,

Abdul Latiff,

Aggelidis

et al. 2023

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

IntroductionThe integrated care pathways for atopic dermatitis (AD‐ICPs) aim to bridge the gap between existing AD treatment evidence‐based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co‐ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems.MethodsThe GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD‐ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres.ResultsThe AD‐ICPs outline the diagnostic procedures, possible co‐morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD.ConclusionThe AD‐ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.

show abstract

“…This disease persists throughout the life of these patients, from infantile to adults stages, and greatly impacts their daily lives, as well as social and leisure activities 3 . In China, as determined in 2019, AD has been reported to be the 24th most burdensome of the 369 most commonly identified diseases and is a notable source of public health concern 4 . In children, irritant dermatitis and food allergies are typical aggravating conditions, while sweating and psychological stress significantly impact AD occurrence in adults 3 .…”

Section: Introductionmentioning

confidence: 99%

Identification of novel candidate genes and predicted miRNAs in atopic dermatitis patients by bioinformatic methods

Chen

Xin

Wang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common, chronic inflammatory dermatosis with relapsing eruptions. Our study used bioinformatics to find novel candidate differentially expressed genes (DEGs) and predicted miRNAs between AD patients and healthy controls. The Mesh term “atopic dermatitis” was retrieved to obtain DEGs in GEO datasets. DEGs between AD patients and healthy controls were analyzed using GEO2R. Overlapping DEGs between different datasets were obtained with use of Draw Venn software. GO and KEGG enrichment analyses were conducted by the use of DAVID. STRING and miRWalk were used to individually analyze PPI networks, interactions of candidate genes and predicted miRNAs. A total of 571 skin samples, as retrieved from 9 databases were assessed. There were 225 overlapping DEGs between lesioned skin samples of AD patients and that of healthy controls. Nineteen nodes and 160 edges were found in the largest PPI cluster, consisting of 17 up-regulated and 2 down-regulated nodes. Two KEGG pathways were identified, including the cell cycle (CCNB1, CHEK1, BUB1B, MCM5) and p53 (CCNB1, CHEK1, GTSE1) pathways. There were 56 nodes and 100 edges obtained in the miRNA-target gene network, with has-miR-17-5p targeted to 4 genes and has-miR-106b-5p targeted to 3 genes. While these findings will require further verification as achieved with experiments involving in vivo and in vitro modles, these results provided some initial insights into dysfunctional inflammatory and immune responses associated with AD. Such information offers the potential to develop novel therapeutic targets for use in preventing and treating AD.

show abstract

The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019

Cited by 13 publications

References 30 publications

Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis

Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

Identification of novel candidate genes and predicted miRNAs in atopic dermatitis patients by bioinformatic methods

Contact Info

Product

Resources

About

The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019

Cited by 13 publications

References 30 publications

Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis

Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis

A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Identification of novel candidate genes and predicted miRNAs in atopic dermatitis patients by bioinformatic methods

Contact Info

Product

Resources

About

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative